Docs use 3-D printed models to prepare for surgery; Big Data healthcare consultancy raises $17.5M;

@FierceMedDev: UPDATED with interview of CEO: TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report | Follow @FierceMedDev

@VarunSaxena2: Crowdsourcing challenge winner looking to commercialize NIH tech to diagnose brain cancer. Article | Follow @VarunSaxena2

@EmilyWFierce: Congress urges feds to probe FDA over morcellator safety concerns. More | Follow @EmilyWFierce

> Four children with malformed blood vessels in their brain benefited from 3-D printing of their anatomy prior to the high-risk corrective procedures. "These children had unique anatomy with deep vessels that were very tricky to operate on," said Boston Children's neurosurgeon Dr. Edward Smith. "The 3-D-printed models allowed us to rehearse the cases beforehand and reduce operative risk as much as we could. You can physically hold the 3-D models, view them from different angles, practice the operation with real instruments and get tactile feedback." More

> Zephyr Health raised $17.5 million in equity. The company uses Big Data to offer market insights to medical device and pharma companies. More

> Waste management company Rubicon Global is expanding its focus to include the disposal of waste produced by hospitals. More

Biotech News

@FierceBiotech: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology. News | Follow @FierceBiotech

@JohnCFierce: Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership. Article | Follow @JohnCFierce

@DamianFierce: Like most people, I'm waiting for Thug_BioAnalyst to weigh in before I form an opinion on anything this morning. | Follow @DamianFierce

> Karyopharm tanks as sepsis scares plague its cancer contender. Article

> Sorrento's biotech buyouts bag CAR-T drugs. Item

> Gates backs a $120M breakout round for CRISPR/Cas9 pioneers at Editas. Story

Pharma News

@FiercePharma: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI last week: Aprecia is building $25M plant where it will do 3D printing of drugs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Orexigen picks up new trial tab to settle Contrave dispute with partner Takeda. More | Follow @CarlyHFierce

> GSK defends low-margin strategy with a gloomy outlook for high drug prices. More

> Lilly chalks up a win for Cymbalta in first U.S. trial over withdrawal symptom claims. Article

Animal Health News

> Aratana continues to trim losses in Q2 as it focuses on animal treatments. News

> Merck to partner with National Milk Producers group on training and animal care. Report

> USDA grants conditional license to Zoetis for canine anti-itch therapy. Story

> Feds indict four with smuggling bogus pet products into the U.S. Item

> Dechra to buy control of Croatian animal vaccine maker for $56.4M. Article

Biotech IT News

> Apple's ResearchKit goes global as heart study expands into Hong Kong and U.K. Item

> IBM makes $1B bid for Merge to bolster Watson's image analytics capabilities. Report

> Teva buys majority stake in Immuneering to access genome analysis tools. More

> Illumina strikes deal to buy LIMS provider GenoLogics. Article

> FDA makes its first approval of a 3D-printed drug. Story

Pharma Marketing News

> Allergan plots Namzaric DTC campaign to shore up its Namenda defenses. Item

> Amarin case could unleash a flood of off-label promos. Report

> Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. More

> Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness. Story

> Big Pharma feeds controversy by routing big bucks to private CME. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.